{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:50:42Z","timestamp":1789041042072,"version":"build-2803163510"},"reference-count":83,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["UG1HL069254"],"award-info":[{"award-number":["UG1HL069254"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022852","name":"Centre for Air Pollution, Energy and Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022852","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA040214"],"award-info":[{"award-number":["P30CA040214"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA BC 011823"],"award-info":[{"award-number":["ZIA BC 011823"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006058","name":"St. Baldrick's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015015","name":"Government of South Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018758","name":"Pediatric Transplantation and Cellular Therapy Consortium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018758","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jtct.2023.08.030","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T05:00:48Z","timestamp":1694235648000},"page":"674-684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["INSPIRED Symposium Part 2: Prevention and Management of Relapse Following Chimeric Antigen Receptor T Cell Therapy for B Cell Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7781-2918","authenticated-orcid":false,"given":"Adam J.","family":"Lamble","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Moskop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-8420","authenticated-orcid":false,"given":"Michael A.","family":"Pulsipher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-8736","authenticated-orcid":false,"given":"Shannon L.","family":"Maude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1769-7388","authenticated-orcid":false,"given":"Corinne","family":"Summers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Annesley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0480-3911","authenticated-orcid":false,"given":"Persis","family":"Amrolia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.08.030_bib0001","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.030_bib0002","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.030_bib0003","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.08.030_bib0004","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0005","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0006","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0007","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","volume":"7","author":"Lamble","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.08.030_bib0008","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1200\/JCO.22.01076","article-title":"Outcomes after nonresponse and relapse post-tisagenlecleucel in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia","volume":"41","author":"Schultz","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0009","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0010","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.030_bib0011","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0012","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.08.030_bib0013","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.3390\/ijms24065688","article-title":"CAR T-cell persistence correlates with improved outcome in patients with B-cell lymphoma","volume":"24","author":"Wittibschlager","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtct.2023.08.030_bib0014","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2023.08.030_bib0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.omto.2023.04.003","article-title":"Durable remission related to CAR-T persistence in R\/R B-ALL and long-term persistence potential of prime CAR-T","volume":"29","author":"Shiqi","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jtct.2023.08.030_bib0016","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2023.08.030_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006596","article-title":"CAR T-cell detection scoping review: an essential biomarker in critical need of standardization","volume":"11","author":"Turicek","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2023.08.030_bib0018","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jtct.2021.10.003","article-title":"Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage","volume":"28","author":"Summers","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.08.030_bib0019","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jtct.2023.08.030_bib0020","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.08.030_bib0021","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1182\/blood-2021-147299","article-title":"Outcomes after reinfusion of CD19-specific chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"138","author":"Myers","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.030_bib0022","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/bloodadvances.2019000449","article-title":"More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling","volume":"3","author":"Bader","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.08.030_bib0023","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1002\/cpz1.383","article-title":"Measurable residual disease detection in B-acute lymphoblastic leukemia: the Children's Oncology Group (COG) method","volume":"2","author":"Borowitz","year":"2022","journal-title":"Curr Protoc"},{"key":"10.1016\/j.jtct.2023.08.030_bib0024","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1365-2141.2005.05401.x","article-title":"Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR","volume":"128","author":"Kerst","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0025","unstructured":"Adaptive Biotechnologies. clonoSEQ. Available at: https:\/\/www.clonoseq.com\/. Accessed August 1, 2023."},{"key":"10.1016\/j.jtct.2023.08.030_bib0026","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/bloodadvances.2023009856","article-title":"Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation","volume":"7","author":"Liang","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.08.030_bib0027","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/MOH.0000000000000685","article-title":"Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia","volume":"28","author":"Qayed","year":"2021","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0028","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jtct.2021.08.016","article-title":"Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year","volume":"27","author":"Heslop","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.08.030_bib0029","first-page":"4118","article-title":"Children's Oncology Group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse","author":"Hogan","year":"202341","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0030","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/bloodadvances.2021006035","article-title":"Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy","volume":"6","author":"Holland","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.08.030_bib0031","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41375-022-01546-9","article-title":"CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study","volume":"36","author":"Jacoby","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.08.030_bib0032","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0033","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41375-022-01740-9","article-title":"Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia","volume":"37","author":"Ceolin","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.08.030_bib0034","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jtct.2023.02.012","article-title":"The choice of either conventional chemotherapy or inotuzumab ozogamicin as bridging regimen does not appear to impact clinical response to CD19-directed CAR-T therapy in pediatric B-ALL","volume":"29","author":"Rubinstein","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.08.030_bib0035","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.25582","article-title":"Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial","volume":"94","author":"Jiang","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0036","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world Chimeric Antigen Receptor Consortium Report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0037","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jtct.2021.11.014","article-title":"Impact of bridging chemotherapy on clinical outcomes of CD19-specific CAR T cell therapy in children\/young adults with relapsed\/refractory B cell acute lymphoblastic leukemia","volume":"28","author":"Shahid","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.08.030_bib0038","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","article-title":"Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia","volume":"6","author":"Dekker","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.08.030_bib0039","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.08.030_bib0040","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.08.030_bib0041","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2021-148652","article-title":"Impact of allogeneic hematopoietic cell transplantation (HCT) as consolidation following CD19 chimeric antigen receptor (CAR) T cell therapy for treatment of relapsed acute lymphoblastic leukemia (ALL)","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.030_bib0042","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.2022016937","article-title":"How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL","volume":"141","author":"Myers","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.030_bib0043","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jtct.2021.10.011","article-title":"Factors impacting overall and event-free survival following post-chimeric antigen receptor T cell consolidative hematopoietic stem cell transplantation","volume":"28","author":"Molina","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.08.030_bib0044","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1182\/blood-2021-152344","article-title":"ALL maintenance treatment for early loss of B-cell aplasia after tisagenlecleucel therapy","volume":"138","author":"Gabelli","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.030_bib0045","unstructured":"Krupski C, Baggott C, John S, et al. Outcomes following tisagenlecleucel reinfusion in children and young adults with B-cell acute lymphocytic leukemia. Presented at: 2023 Transplantation & Cellular Therapy Meetings, Abstract LBA4. February 18, 2023; Orlando, FL."},{"key":"10.1016\/j.jtct.2023.08.030_bib0046","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004483","article-title":"Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation","volume":"10","author":"Holland","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2023.08.030_bib0047","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.030_bib0048","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1182\/bloodadvances.2022007246","article-title":"Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium","volume":"7","author":"Stefanski","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.08.030_bib0049","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","article-title":"Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells","volume":"18","author":"Stroncek","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2023.08.030_bib0050","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/trf.15287","article-title":"Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics","volume":"59","author":"Elavia","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.jtct.2023.08.030_bib0051","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study","volume":"15","author":"Shah","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0052","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","article-title":"Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.030_bib0053","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005701","article-title":"Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory B-ALL","volume":"11","author":"Song","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2023.08.030_bib0054","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/ajh.25108","article-title":"Potent anti-leukemia activities of humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"93","author":"Cao","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0055","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0056","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.16623","article-title":"Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory\/relapsed B acute lymphoblastic leukaemia","volume":"191","author":"Wang","year":"2020","journal-title":"Br J Haematol"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2023.08.030_bib0057","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2019-131346","article-title":"Novel CD19t T-antigen presenting cells expand CD19 CAR T cells in vivo","volume":"134","author":"Annesley","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.030_bib0058","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0059","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2023.08.030_bib0060","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.030_bib0061","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2023.08.030_bib0062","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.030_bib0063","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.22.01214","article-title":"Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jtct.2023.08.030_bib0064","doi-asserted-by":"crossref","first-page":"e19508","DOI":"10.1200\/JCO.2022.40.16_suppl.e19508","article-title":"CAR T-cells effective for post-CART relapse: a new treatment paradigm","volume":"40","author":"Holland","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0065","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s41375-019-0580-z","article-title":"Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19","volume":"34","author":"Asnani","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.08.030_bib0066","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2023.08.030_bib0067","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/bloodadvances.2018018093","article-title":"Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL","volume":"2","author":"W\u00f6lfl","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.08.030_bib0068","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001563","article-title":"Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia","volume":"8","author":"Mo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2023.08.030_bib0069","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.030_bib0070","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.21.01693","article-title":"Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children's Oncology Group Protocol AALL1621","volume":"40","author":"O'Brien","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jtct.2023.08.030_bib0071","doi-asserted-by":"crossref","first-page":"10519","DOI":"10.1200\/JCO.2020.38.15_suppl.10519","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0072","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2023.08.030_bib0073","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2023.08.030_bib0074","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.08.030_bib0075","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2023.08.030_bib0076","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s12885-022-09489-1","article-title":"Humanized CD19 CAR-T cells in relapsed\/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy","volume":"22","author":"An","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtct.2023.08.030_bib0077","article-title":"Long-term safety and efficacy of CD19 humanized selective CAR-T therapy in B-ALL patients who have previously received murine-based CD19 CAR-T therapy","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0078","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1002\/ajh.26123","article-title":"Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed\/refractory pediatric acute lymphoblastic leukemia","volume":"96","author":"Wang","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2023.08.030_bib0079","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1182\/bloodadvances.2022009480","article-title":"Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy","volume":"7","author":"Lee","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.08.030_bib0080","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.030_bib0081","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1016\/S2352-3026(22)00225-3","article-title":"Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study","volume":"9","author":"Ghorashian","year":"2022","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2023.08.030_bib0082","doi-asserted-by":"crossref","first-page":"10352","DOI":"10.1182\/blood-2022-164879","article-title":"Dual antigen targeting with co-transduced CD19\/22 CAR T cells may prevent antigen-negative relapse after CAR T cell therapy for relapsed\/refractory ALL","volume":"140","author":"Ghorashian","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.08.030_bib0083","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1182\/blood-2021-148881","article-title":"SCRI-CAR19\u00d722v2 T cell product demonstrates bispecific activity in B-ALL","volume":"138","author":"Annesley","year":"2021","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723015117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723015117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:10:43Z","timestamp":1763003443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723015117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":83,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2666636723015117"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.08.030","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"INSPIRED Symposium Part 2: Prevention and Management of Relapse Following Chimeric Antigen Receptor T Cell Therapy for B Cell Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.08.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}